In the CRISPR tea leaves

The four foundational CRISPR companies have stayed tight-lipped about their plans and progress, providing few details about their development strategies or intended indications. But as they have ramped up partnering in the last few months and started to beef up their IP portfolios, the companies are disclosing more information, yielding a picture of what questions each company sees as a priority to address and how it plans to do so.

The increased openness is driven largely by the fact that two of the four have gone public this year, according to Rachel Haurwitz, president and CEO of Caribou Biosciences Inc., the only member of the pack that has not yet announced IPO plans. ...